Fresenius Kabi enters into joint venture to advance new cell and gene therapies

January 21, 2020

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No financial terms were disclosed.